EGFRvIII mediates RIP1 K63 ubiquitination while RIP1 interacts with NEMO and TAK1 to activate NF-κB, which modulates tumorigenesis and efficacy of targeted treatment in GBM [192]. The gene discussed is RIPK1; the disease is glioblastoma.